Shearman & Sterling advised Swiss Novartis Group as lead counsel in its €925 million (US$1.2 billion) all-cash acquisition of the specialty generic injectables business of EBEWE Pharma, providing Sandoz (Novartis Group's generic pharmaceuticals division) an opportunity to create a strong global platform for future growth.

The Shearman & Sterling M&A team in this transaction was headed by Harald Selzner, a partner in the Corporate/M&A Group and located in the Düsseldorf office. Other principal Shearman & Sterling attorneys involved in the M&A aspects of the transaction include partners George A. Casey (New York), George Karafotias (London) and Samuel A. Waxman (New York), as well as associates Thankmar Wagner (Düsseldorf), David Plattner (London) and Giuseppe Sferrazza (Düsseldorf).

The Shearman & Sterling antitrust team in this transaction includes partner Hans Jürgen Meyer-Lindemann and counsel Mathias Stöcker (both Düsseldorf).

Shearman & Sterling also advised on compliance aspects of the transaction. The Shearman & Sterling compliance team in this transaction includes partners Richard H. Kreindler (Frankfurt) and Philip E. Urofsky (Washington, D.C.), as well as counsel Joachim Grittmann and associate Amy F. Cohen (both Frankfurt).

For more information, please contact: Dr. Hans Jürgen Meyer-Lindemann | Düsseldorf | T +49 211 17888 719 |